Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
1009344-33-5 | Azetukalner | ChemScene
azetukalner
AZETUKALNER
Azetukalner | C23H29FN2O | CID 24743936 - PubChem
Azetukalner – Application in Therapy and Current Clinical Research
Azetukalner (XEN1101) | Kv7.2/Kv7.3 opener | Probechem Biochemicals
Azetukalner Shows Promise in Early Trial for Treating Depression and ...
Xenon Pharmaceuticals Unveils Promising 36-Month Azetukalner Data on ...
Understanding the Mechanism and Rationale of Azetukalner to Treat Focal ...
Xenon Pharmaceuticals to present new long-term data for Azetukalner in ...
Interim analysis of the long‐term efficacy and safety of azetukalner in ...
Study on the Safety and Effectiveness of Azetukalner for Adults with ...
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at ...
Study on the Long-term Safety and Tolerability of Azetukalner for ...
Interim Analysis Highlights Long-Term Safety of Azetukalner for Focal ...
Estudio sobre la seguridad y eficacia de Azetukalner en pacientes con ...
Xenon targets NDA filing for azetukalner within 6 months of phase III ...
The NEW treatment - Azetukalner !! - YouTube
Xenon to Present New Azetukalner Epilepsy Data at AES 2025
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 | The ...
Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With ...
Long-Term Safety and Efficacy of Azetukalner (XEN1101), a Novel, Potent ...
Azetukalner (XEN1101) | KCNQ2/3激活剂 | MCE
A profile of azetukalner for the treatment of epilepsy: from ...
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 ...
Promising 48-Month Azetukalner Epilepsy Study Data by Xenon
Xenon Showcases New 48-Month Azetukalner OLE Study Data in
العلاج الجديد للصرع - Azetukalner - YouTube
Azetukalner：一种新型KV7钾通道开放剂在治疗重度抑郁症中显示出前景 – Medxy AI
大うつ病アゼツカルネルAzetukalner：新規KV7カリウムチャネルオープナー 治療薬可能性｜Makisey
Xenon Stock: 2025 Could Be Pivotal For Azetukalner’s Epilepsy Potential ...
(PDF) A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel ...
Azetukalner(Azetukalner) - 药物靶点：Kv7.2 x Kv7.3_在研适应症：躁郁症1型，躁郁症2型，重度抑郁症 ...
Xenon Pharmaceuticals Breakthrough: Azetukalner's Milestone Approval ...
Potent KV7 potassium channel opener shows promise in MDD treatment ...
Understanding the Therapeutic Potential and Promising Early-Stage Data ...
Azetukalner(Azetukalner) - 药物靶点：Kv7.2 x Kv7.3_在研适应症：躁郁症，抑郁症，躁郁症1型_专利_临床_研发
Recent Advances in Synthetic Routes to Azacycles
A sustainable and chemoselective continuous flow hydrogenation of ...
Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major ...
Azetukalner, a Novel, Potent KV7 Potassium Channel Opener in ...
Xenon Pharmaceuticals: Azetukalner's 2026 Data Readouts and Multi ...
Promising Long-Term Results for Novel Antiseizure Med
mzCloud – Kresoxim methyl
JAMA子刊：新药快效抗抑郁，1周症状即有所改善！-MedSci.cn
抑郁症治疗-临床进展-Kv7通道开放剂Azetukalner抗抑郁 - 知乎
Dicobalt-catalyzed N=N coupling reactions of tertiary alkyl azides to ...
Progress report on new medications for seizures and epilepsy: A summary ...
Xenon Pharmaceuticals Inc. präsentiert Daten aus der klinischen Phase-2 ...
Xenon Pharmaceuticals, Inc. (Xenon Pharmaceuticals, Inc.) - 药物管线_专利_临床 ...
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Reports Q4 and Full-Year 2025 ...
XEN1101, a Novel Potassium Channel Opener has Potential as Novel ...
KCNQ2 and KCNQ3 show permeant ion regulation and pharmacology ...
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates ...
